Eli Lilly and Company(@EliLillyandCo):It's not just about weight. In TRIUMPH-1, Lilly’s investigational triple agonist reduced knee osteoarthritis pain by an average of 73% at the 12 mg dose and moderate-to-severe obstructive sleep apnea severity by an average of 61% at the 9 mg dose for people living with obesity. Presented today at #ADA2026. Read more:

Eli Lilly and Company

@EliLillyandCo

Uniting caring with discovery to create medicines that make life better worldwide. Lilly’s official account (formerly LillyPad)

Joined July 2010

1.2K Following 145.5K Followers

Eli Lilly and Company@EliLillyandCo

2026.06.06 20:09

It's not just about weight. In TRIUMPH-1, Lilly’s investigational triple agonist reduced knee osteoarthritis pain by an average of 73% at the 12 mg dose and moderate-to-severe obstructive sleep apnea severity by an average of 61% at the 9 mg dose for people living with obesity. Presented today at #ADA2026#. Read more: